scholarly journals Current Advances in Clinical Application of Liquid Biopsy

2021 ◽  
Author(s):  
Shawn Baldacchino
Keyword(s):  
Early Detection ◽  
Liquid Biopsy ◽  
Early Detection Of Cancer ◽  
Clinical Applications ◽  
Advanced Stage ◽  
Circulating Tumour Cells ◽  
Detailed Review ◽  
Companion Diagnostic ◽  
Diagnostic Approaches ◽  
Circulating Tumour Dna

Liquid biopsy solutions are available for niche clinical applications. The patient benefits of such solutions are evident: ease of sampling, acceptable and repeatable. To date a number of solutions have received regulatory approval with more comprehensive, multi-cancer companion diagnostic approaches receiving approval in late 2020. Given these breakthrough advances and the ongoing clinical studies in early detection of cancer, the liquid biopsy field is making strides in technology. While circulating tumour DNA (ctDNA) solutions are quickly penetrating the market, strides in circulating tumour cells (CTC) and extracellular vesicles (EV) technologies is unlocking their potential for liquid biopsy. ctDNA solutions are paving the way towards clinical translation into the distinct applications across the cancer continuum. This chapter presents a detailed review of current approved liquid biopsy tests and provides a summary of advanced-stage prospective technologies within the context of distinctive clinical applications.

scholarly journals Circulating Tumor Cells: Liquid Biopsy for Early Detection of Cancer

2019 ◽  
Vol 25 (1) ◽  
pp. 1-9
Author(s):  
Benjamin Mwesige ◽  
Seung-Gu Yeo ◽  
Byong Chul Yoo
Keyword(s):  
Early Detection ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Early Detection Of Cancer

scholarly journals Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma – What is the Role of Liquid Biopsy in Breast Cancer?

2017 ◽  
Vol 77 (12) ◽  
pp. 1291-1298 ◽  
Author(s):  
Arkadius Polasik ◽  
Marie Tzschaschel ◽  
Fabienne Schochter ◽  
Amelie de Gregorio ◽  
Thomas Friedl ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liquid Biopsy ◽  
Venous Blood ◽  
Metastatic Breast ◽  
Tumour Cells ◽  
Circulating Microrna ◽  
Circulating Tumour Cells ◽  
Repeated Testing ◽  
Metastatic Breast Carcinoma ◽  
Circulating Tumour Dna

AbstractDissemination of tumour cells and the development of solid metastases occurs via blood vessels and lymphatics. Circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) can be detected in venous blood in patients with early and metastatic breast cancer, and their prognostic relevance has been demonstrated on numerous occasions. Repeated testing for CTCs and ctDNA, or regular so-called “liquid biopsy”, can be performed easily at any stage during the course of disease. Additional molecular analysis allows definition of tumour characteristics and heterogeneity that may be associated with treatment resistance. This in turn makes personalised, targeted treatments possible that may achieve both improved overall survival and quality of life.

scholarly journals Liquid Biopsy in Breast Cancer

2020 ◽  
Vol 80 (11) ◽  
pp. 1093-1104
Author(s):  
Maggie Banys-Paluchowski ◽  
Natalia Krawczyk ◽  
Tanja Fehm
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Liquid Biopsy ◽  
Prognostic Significance ◽  
Metastatic Breast ◽  
Therapeutic Interventions ◽  
Response To Treatment ◽  
Circulating Tumour Cells ◽  
Treatment Research ◽  
Circulating Tumour Dna

AbstractIn recent years, the blood-based analysis of circulating tumour cells (CTCs) and nucleic acids (DNA/RNA), otherwise known as liquid biopsy, has become increasingly important in breast cancer. Numerous trials have already underscored the high prognostic significance of CTC detection in both early and metastatic stages. Moreover, the changes in CTC levels and circulating tumour DNA (ctDNA) during the course of the disease correlate with the response to treatment. Research currently focuses on liquid-biopsy based therapeutic interventions in metastatic breast cancer. In this context, alpelisib, a PI3K inhibitor, was the first agent to be approved by FDA and EMA.

Values of liquid biopsy in early detection of cancer: results from meta-analysis

2021 ◽  
pp. 1-11
Author(s):  
Sinong Jia ◽  
Li Xie ◽  
Lei Li ◽  
Ying Qian ◽  
Jie Wang ◽  
...  
Keyword(s):  
Early Detection ◽  
Liquid Biopsy ◽  
Early Detection Of Cancer ◽  
Meta Analysis

scholarly journals Early detection of cancer in Nepal: Role of liquid biopsy

2018 ◽  
Vol 8 (2) ◽  
pp. 1399-1407
Author(s):  
Sameer Chhetri Aryal ◽  
Gopi Aryal
Keyword(s):  
Cancer Screening ◽  
Early Detection ◽  
Liquid Biopsy ◽  
Early Detection Of Cancer ◽  
Cancer Control ◽  
Target Population ◽  
Population Based ◽  
Warning Signs ◽  
Screening Programs

Cancers of the uterine cervix, breast, lung and stomach are four of the most common cancers in Nepal. Lack of knowledge and awareness about cancer, its risk factors and negligence of the early warning signs play crucial role in raising the incidence of the cancer. Curative therapies are most successful when cancer is diagnosed and treated at an early stage.Organized cancer screening programmes provide screening to target population and use multidisciplinary delivery teams, coordinated clinical oversight committees, and regular review by a multidisciplinary evaluation board. For population-based screening programs, decision- making and governance structures, tasks and procedures need to be defined.In this paper, we review population-based cancer screening programmes of different countries and share recommendations and relevant evidence for screening and early detection of common cancers in Nepal. The evidence-based recommendations provided in this Review are intended to act as a guide for policy makers, clinicians, and public health practitioners who are developing and implementing strategies in cancer control.  We also discuss the role of liquid biopsy in early detection, diagnosis and monitoring of cancers using circulating biomarkers. Despite challenges, time has come to include cell free circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), as a parameters for early detection of cancer in the days to come.

977: Circulating free DNA: a ‘liquid biopsy’ for the early detection of cancer?

2014 ◽  
Vol 50 ◽  
pp. S238
Author(s):  
R.M. Trigg ◽  
S.M. Giblett ◽  
C.A. Pritchard ◽  
J.A. Shaw
Keyword(s):  
Early Detection ◽  
Liquid Biopsy ◽  
Early Detection Of Cancer ◽  
Circulating Free Dna ◽  
Free Dna
Sign in / Sign up

Export Citation Format

Share Document